NCT01657162View on ClinicalTrials.gov

Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis

PHASE3CompletedINTERVENTIONAL

Enrollment

1,139

Participants

Timeline

Start Date

November 20, 2012

Primary Completion Date

October 3, 2016

Study Completion Date

October 3, 2016

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG

Alendronate

Alendronate is a bisphosphonate drug that prevents bone resorption by osteoclast and is used for the treatment of osteoporosis.

Trial Locations (25)

Unknown

Lakewood

Hialeah

Bethesda

Buenos Aires

Brasília

Curitiba

Rio de Janeiro

São Paulo

Vitória

Brno

Pardubice

Vinohrady

Aalborg

Ballerup Municipality

Vejle

Tallinn

Tartu

Hong Kong

Vilnius

Bialystok

Kielce

Lodz

Warsaw

Zgierz

Bucharest

All Listed Sponsors

lead

Radius Health, Inc.

INDUSTRY

NCT01657162 - Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis | Biotech Hunter | Biotech Hunter